Two cases of euglycemic diabetic ketoacidosis caused by dapagliflozin

Year 2022, Volume: 49 Issue: 2, 385 - 389, 13.06.2022

Necla Güngörler Leyla Seyhan Zafer Pekkolay

https://doi.org/10.5798/dicletip.1129522

Abstract

Two cases of euglycemic diabetic ketoacidosis caused by dapagliflozin

Abstract

Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH <7.3), ketosis (ketonemia or ketonuria) are stated as diagnostic criteria for diabetic ketoacidosis. Diabetic ketoacidosis can rarely be seen in blood glucose below 250 mg/dL. This condition is called euglycemic diabetic ketoacidosis. Although it is a rare condition, since a normal glucose level may exclude the diagnosis, it may cause a delay in treatment and consequently increase morbidity and mortality. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are new generation oral anti-diabetic drugs used in the treatment of diabetes mellitus. It can cause rare but serious complications, such as euglycemic diabetic ketoacidosis. With these case reports, we aimed to raise awareness about euglycemic diabetic ketoacidosis.

Keywords

Dapagliflozin, euglycemic ketoacidosis, sodium-glucose co-transporter 2 (SGLT-2) inhibitors

References

• 1.Saeedi P, Petersohn I, Salpea P, et al. Global andregional diabetes prevalence estimates for 2019 andprojections for 2030 and 2045: Results from theInternational Diabetes Federation Diabetes Atlas.Diabetes Res Clin Pract. 2019; 157:107843.
• 2.Nyenwe EA, Kitabchi AE. The evolution of diabeticketoacidosis: An update of its etiology, pathogenesisand management. Metabolism. 2016;65(4):507-21.
• 3.Dhatariya, K.K., Glaser, N.S., Codner, E. et al.Diabetic ketoacidosis. Nat Rev Dis Primers 6, 40(2020). https://doi.org/10.1038/s41572-020-0165-1.
• 4. Plosker GL. Dapaglifozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.